Alnylam Pharmaceuticals Touts AMVUTTRA Momentum, Teases Key Pipeline Readouts at TD Cowen Conf. [Yahoo! Finance]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Yahoo! Finance
and mid-to-high-20s first-line share, and it reiterated 2026 TTR franchise revenue guidance of $4.4–$4.7 billion under its Alnylam 2030 growth framework. Nucresiran TRITON enrollment is on track; the next-generation TTR candidate targets ~95% TTR knockdown (vs mid-80s today) and is in two phase 3 programs—polyneuropathy (targeting ~2028 launch) and a ~1,200-patient cardiomyopathy outcomes study with expected readout/launch around 2030—which Alnylam says could consolidate the franchise and expand margins. Multiple non-TTR readouts are expected by year-end, including phase 2 proof-of-concept data for diabetes candidate REV-14, phase 2 HHT data for the plasminogen program, and phase 1b safety/knockdown data in Huntington's, while zilebesiran progresses in a phase 3 hypertension outcomes trial. Interested in Alnylam Pharmaceuticals, Inc.? Here are five stocks we like better. Alnylam Stock Soars 65%: Find Out What's Behind the Gains Alnylam Pharmaceuticals (NASDAQ:ALNY) executive
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments [Yahoo! Finance]Yahoo! Finance
- Helix Announces Multi-Year Agreement with Alnylam to Drive Precision Medicine Development [Yahoo! Finance]Yahoo! Finance
- Alnylam's research pact worth up to $1.1B sends Tenaya higher [Seeking Alpha]Seeking Alpha
- Alnylam Reimbursement Win And Trial Progress Versus Current Valuation Signals [Yahoo! Finance]Yahoo! Finance
- Alnylam Pharmaceuticals, Inc. (ALNY) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]Seeking Alpha
ALNY
Earnings
- 2/12/26 - Beat
ALNY
Sec Filings
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- ALNY's page on the SEC website